1. The plaintiff's primary and conjunctive claims are all dismissed.

2. The costs of lawsuit shall be borne by the Plaintiff.

Basic Facts

On March 22, 2013, the Plaintiff and the Defendant entered into a contract with the Plaintiff to sell and sell the instant product to the Defendant’s agency in Seoul, Gyeonggi-do, etc. (hereinafter “instant contract”). The Plaintiff and the Plaintiff, as the Defendant’s agent, supplied DV New’s main research subjects and DV New H.C.et (hereinafter “instant product”).

The main contents of the instant contract are as follows.

Article 1 (Purpose of Contract) The defendant sells and supplies products to the plaintiff and the plaintiff sells the products as the defendant's agent.

Article 2 (Definition of Products) The term in this Agreement is to combine the DV New Pharma, Pteril H.C. and Pteril H.C.et.

In other words, one product includes one DV New Hma, one subject, and H.C.et.

Article 12 (Return of Goods) No goods supplied by the defendant to the plaintiff shall be returned, except in any of the following cases:

4. In the event of failure to obtain a non-benefit code from ordinary members for the Set, all products shall be returned.

According to the instant contract, the supply price of the instant product is KRW 40,000 per unit of DV New, and is KRW 20,000 per unit of Stere H.C., and KRW 50,000 per unit of DV New, and KRW 30,000 per unit of Stile H.C., if the supply price of the instant product was purchased more than the minimum purchase volume, including value added tax.

On April 10, 2013, 120,000,000, 72,150,000 on April 24, 2013, 2013, June 28, 2013, 1,950,000 on July 2, 2013, 780,000 on July 17, 2013, 200, 780,000 on August 390, 200, 200 on September 38, 2013, 850,000,000 on September 1, 2013, 200, 10,560,000 on September 1, 203, 200, 10,560, 100, 301, 301, 301, 2013

[Reasons for Recognition] The parties to a judgment as to the absence of dispute, entry of Gap evidence 1, the purport of the entire pleadings, and the primary claim.